The study aimed to evaluate the equivocal HER2 (IHC 2+) status of breast cancer using intra- and peritumoral radiomics features of contrast-enhanced mammography (CEM).<h4>Methods</h4>A total of 131 breast cancer patients with equivocal HER2 (IHC 2+) status of breast cancer were enrolled in the study and divided into training (n=84), internal test (n=22) and prospective test (n=25) cohorts. The gene discussed is ERBB2; the disease is breast carcinoma.